This article is also available as a podcast in more than 20 languages. Click the ⚙️ Settings icon on YouTube, then choose Audio Track and Subtitles to watch it in your preferred language.
The pharmaceutical industry uses disinfectants to… disinfect cleanrooms.
Even though manufacturers have already demonstrated their effectiveness, disinfectants still have to be revalidated by the manufacturer, under their own conditions of use.
This essential step is called disinfectant validation.
And it is not an easy task … many laboratories struggle with it.
To better understand what disinfectant validation really involves, we spoke with a SuperMicrobiologist and expert in the field: Ségolène Lebrun.
Disinfectants Validation : definition and requirements
In simple words, how would you define “disinfectant validation”?
Ségolène Lebrun: Disinfectant validation is a process used to demonstrate that a disinfectant product (only a disinfectant, not a detergent) is effective:
- on a specific surface,
- against a type of microorganism,
- using specific strains,
- for a defined contact time,
- with or without mechanical action.
The goal is to show that the disinfectant achieves the expected log reduction under real conditions of use.
Is disinfectant validation a regulatory requirement?
Yes, clearly for sterile pharmaceutical manufacturing, it is a regulatory requirement described in Annex 1.
For the rest of the pharmaceutical industry, Annex 15 refers to the validation of cleaning and disinfection processes, without explicitly requiring disinfectant validation. However, inspectors’ expectations are high, especially through FDA and PIC/S guidelines.
In practice, not validating disinfectants has become very risky.
Is disinfectant validation the same as cleaning validation?
No. These are two completely different validations.
- Disinfectant validation evaluates the microbiological effectiveness of a disinfectant.
- Cleaning validation evaluates the ability of a process to remove residues, mainly chemical residues, from production equipment.
Both are important, but they are very different topics and require very different approaches.
Before starting disinfectant validation
How do you choose a “good” disinfectant?
In most cases, when sites start disinfectant validation, disinfectants have already been in use for a long time. So the question of product choice is not often asked at that stage.
However, when a product needs to be selected or replaced, several key criteria must be considered:
- Regulatory compliance
The disinfectant must comply with the European Biocidal Regulation (EU 528/2012). If it does not, it cannot be used. - Microbiological spectrum
The disinfectant must be effective against the site’s environmental flora and the microorganisms the site wants to control (bacteria, yeasts, molds, spores). - Contact time
The contact time must be realistic for cleanroom conditions (air changes, fast drying) and long enough to ensure effectiveness. - Residues
Some disinfectants leave significant residues. This must be considered in the overall decontamination program and when defining cleaning frequency or the need for rinsing. - Material compatibility
Some products may damage or corrode surfaces and equipment. - HSE aspects
Toxicity, odor, PPE requirements, and operator acceptance.
All these criteria must be considered when selecting disinfectants.
Are there other prerequisites before starting validation?
Yes, and they are often underestimated. You must:
- know the site’s environmental flora (which requires adequate environmental monitoring and proper storage of site strains),
- define representative surfaces and collect them as surface coupons for laboratory testing,
- define the amount of product applied to ensure sufficient contact time,
- formalize routine use procedures.
Without this preparation, there is a real risk of having to repeat part of the validation.
What types of surfaces are typically found in pharma cleanrooms?
There are many types of surfaces, but the most common are stainless steel, PVC, glass, epoxy, and polycarbonate.
The goal is to group these surfaces into families and identify worst cases, in order to limit the number of tests. Surface families should behave similarly when exposed to disinfectants.
How can surface type affect disinfectant effectiveness?
Several factors are involved, such as surface porosity, product retention, the ability of microorganisms to hide in micro-cavities, and chemical interactions between the surface and the disinfectant.
Some surfaces can absorb or chemically interact with disinfectants, reducing their effectiveness.
Disinfectant validation in practice
How is disinfectant validation performed?
In the laboratory, representative surface coupons are used.
The general process is:
- inoculation of the coupon with a defined concentration of a strain,
- controlled drying,
- application of the disinfectant (with or without mechanical action),
- respect of the contact time,
- recovery of microorganisms,
- comparison before and after to calculate the log reduction.
Each combination of surface × strain × disinfectant × contact time × mechanical action (or not) is one test condition.
Are there standards or guidelines for these protocols?
Yes. Protocols are clearly described in technical standards such as EN 13697, EN 16777, and EN 13704 for sporicidal activity. These standards define coupon size, application methods, pressure for mechanical action, number of repetitions, and acceptance criteria.
How many tests does this represent?
The number of tests increases very quickly. It depends on the number of strains (Pharmacopoeial and site strains), the number of surfaces, contact times, test conditions (with or without mechanical action).
That is why it is essential to clearly define surface families and microbiological representatives.
Is validation usually done in-house or outsourced?
In most cases, it is outsourced. Disinfectant validation is complex, expensive, performed occasionally, and requires specific expertise. Even very competent microbiology laboratories often rely on specialized service providers.
Why are site strains so important?
Because they represent the real risk for the site. They must be identified, properly characterized, and stored. My advice is to always preserve recurrent strains, such as Micrococcus luteus or certain Staphylococcus species, which are commonly found on pharmaceutical sites.
What if validation fails for a strain?
Several options exist: increasing contact time, changing the application protocol, or replacing the disinfectant. However, this often means repeating part or all of the validation. Specialized laboratories can provide valuable support, but the best approach is to define realistic validation conditions from the start.
In situ verification of disinfectant effectiveness
Is there an in situ validation step after laboratory validation?
Yes, but the wording is important.
It is not really “in situ validation,” but rather verification of cleaning and disinfection effectiveness.
After laboratory validation, the goal is to confirm that under real conditions – disinfectant, surfaces, operator practices, and contact time – microbiological specifications are met in the cleanrooms.
How are in situ tests performed?
In situ tests are very different from laboratory validation. No artificial contamination or deliberate strain introduction is allowed.
Tests rely only on naturally present contamination.
They are performed just after cleaning and disinfection (T0), when surfaces are supposed to be in optimal condition. Surface samples are taken, often multiplying sampling points, surfaces, and operators to assess variability related to human practices.
This is not a validation in the strict sense of Annex 15, but an effectiveness verification study.
Disinfectant validation lifecycle
When should validation be repeated?
Revalidation may be needed in several cases: new facilities, renovations, new equipment, disinfectant changes, changes in frequency or practices, or significant changes in the site microbiome.
If the site flora changes, should disinfectants be revalidated?
The decision to revalidate depends on the microorganism involved and its importance for the site.
For example, if a significant imbalance in the microbiome is observed – typically when environmental flora becomes predominant whereas it was not during the initial validation – then it may be relevant to review the validation scope and consider adding new strains.
The key point is to have clear criteria defined from the start: in which situations is a change considered significant enough to justify revalidation?
The goal is to avoid having to make this decision urgently when a problem arises.
Can microorganisms develop resistance to disinfectants? And if so, should disinfectants be revalidated regularly?
The question is not simple.
When a change in site flora is observed, new microorganisms or an imbalance may indeed appear. However, there is no certainty about the real cause of this change.
Is this variation linked to the development of resistance to disinfectants?
Or is it due to a change in practices, the arrival of a new operator, new flows, a change of supplier, or modifications to the site environment?
In practice, it is impossible to know for sure. Hypotheses can be made, but no formal conclusion can be drawn.
Moreover, in real laboratory life, these situations are often multifactorial. And resistance is usually not the first explanation considered when flora changes.
On paper, resistance can be discussed, but microbiology is never purely theoretical. We work with living organisms, and things are never that simple or linear.
However, if proper rotation between a sporicidal disinfectant and a non-sporicidal disinfectant is applied, the risk of resistance mechanisms is theoretically reduced. That said, this should be stated with caution, because we are dealing with living organisms and unexpected situations can always occur.
In this context, disinfectant resistance should not be the first explanation for a flora imbalance or the appearance of a new microorganism on a site.
Regarding regular revalidation of disinfectants, in practice laboratories do not systematically repeat validations over time, except in cases of change or strong signals.
Even if resistance were to truly occur, it would still be necessary to clearly detect it, demonstrate that it is the same microorganism, and establish a link with the disinfectant used, which is far from obvious in real operational laboratory conditions.
De part ton expérience, comment est gérée ce cycle de vie dans les labos ?
Ma réponse est probablement un peu biaisée, parce que, dans la pratique, je suis surtout contactée par des sites qui ont besoin d’aide pour la validation des désinfectants. Ce sont souvent des laboratoires qui ont quelques connaissances, mais qui ne savent pas forcément comment s’y prendre ou qui se lancent dans le sujet parce qu’ils y sont contraints.
Déjà, le simple fait qu’un site se lance dans une validation des désinfectants, c’est souvent une bonne chose. Mais, très honnêtement, dans mon expérience, la majorité des validations sont réalisées de manière réactive, et non proactive.
Dans beaucoup de cas, les sites se lancent dans la validation des désinfectants après avoir eu des non-conformités en inspection.
Personnellement, et encore une fois cela reflète peut-être le type de missions sur lesquelles j’interviens, je n’ai quasiment jamais été confrontée à des sites qui gèrent de façon proactive le cycle de vie de la validation des désinfectants, avec des revues régulières ou une réflexion anticipée sur les critères de revalidation.
Le cycle de vie est donc souvent sous-représenté, voire peu formalisé, alors même qu’il s’agit d’un élément clé pour maintenir la conformité dans le temps.
What advice would you give to successfully validate disinfectants?
I would say there are three main pieces of advice. Honestly, these three points help avoid about 80% of the problems encountered during disinfectant validation.
First, get support, especially if you are not fully familiar with the topic. Disinfectant validation is complex, with many regulatory requirements, costly tests, and strict protocols. When you lack experience, it is very easy to start incorrectly or miss a critical point.
Second, make a complete inventory of all surfaces present in cleanrooms and, most importantly, anticipate the collection of representative samples of these surfaces.
This is a major difficulty I often see: when validation starts, sites do not have surface coupons to provide to the laboratory. However, these surfaces must represent the materials actually present in the facilities.
If a site is under construction or being renovated, it is essential to keep material offcuts and request samples from suppliers or contractors. This avoids many complications later.
Third, systematically preserve the most frequently detected strains and/or those that are relevant for the site.
All recurrent or relevant strains must be identified, characterized, and stored. When disinfectant validation (or revalidation) needs to be performed, these strains are often unavailable, even though they are essential to represent the site’s real risk.
By applying these three principles – getting expert support, anticipating surface samples, and preserving strains – most difficulties related to disinfectant validation can be avoided.
A big thank you to Ségolène for answering all our questions. If you have any questions about disinfectant validation, feel free to ask them in the comments.
But who is Ségolène Lebrun?
Ségolène Lebrun is a trained microbiologist, with an initial background in laboratory work.
She moved from bench work to roles in responsibility, sterility assurance, and contamination control.
For nearly five years, she has been supporting healthcare industries (pharmaceuticals, medical devices, hospitals) as a consultant.
She is now an independent consultant in microbiology and sterility assurance.
One Response